PMV Pharmaceuticals (PMVP) vs Zhengye Biotechnology (ZYBT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Zhengye Biotechnology (ZYBT) has outperformed PMV Pharmaceuticals (PMVP) over the past year, losing 30.8% versus a loss of 33.6%. Zhengye Biotechnology is the larger company by market cap ($70.1 million vs $66.2 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PMVP | ZYBT |
|---|---|---|
| Share price | $0.876 | $1.48 |
| Market cap | $66.17M | $70.14M |
| 1-day change | -33.13% | -2.63% |
| YTD return | -29.92% | +28.70% |
| 1-year return | -33.64% | -30.84% |
| 5-year return | -96.22% | — |
| EPS (TTM) | $-1.56 | $-0.20 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $16.64M |
| Revenue growth (YoY) | — | -34.83% |
| Net income (latest FY) | $-77.74M | $-9.98M |
| Gross margin | — | 20.51% |
| Operating margin | — | -60.60% |
| Net margin | — | -59.99% |
| 52-week high | $1.91 | $8.01 |
| 52-week low | $0.66 | $0.616 |
| Distance from 52-week high | -54.14% | -81.52% |
| Analyst consensus | strong_buy | — |
| Avg. price target upside | +356.62% | — |
| Average volume | 787.50K | 569.22K |
| Shares outstanding | 75.53M | 47.39M |
| Employees | 54 | 269 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About PMV Pharmaceuticals
PMVP stock →PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule therapies targeting p53 mutations and other p53-related cancers in the United States. It develops rezatapopt, a selective structural corrector of p53 Y220C mutations in Phase 2 clinical trials for tumor agnostic diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 54 employees
About Zhengye Biotechnology
ZYBT stock →Zhengye Biotechnology Holding Limited engages in the research, development, manufacture, and sale of veterinary vaccines for livestock in the People's Republic of China. The company offers vaccines for swine, cattle, goats, sheep, poultry, and dogs, as well as monovalent vaccine, polyvalent vaccine, combined vaccine, and combined and polyvalent vaccine.
Health Care · Biotechnology: Pharmaceutical Preparations · 269 employees
PMVP vs ZYBT FAQ
Which is bigger, PMV Pharmaceuticals or Zhengye Biotechnology?
Zhengye Biotechnology (ZYBT) is larger, with a market capitalization of $70.14M compared with $66.17M for PMV Pharmaceuticals (PMVP).
Which stock has performed better over the past year, PMVP or ZYBT?
ZYBT returned -30.84% over the past 12 months, compared with -33.64% for PMVP (price return, excluding dividends). Past performance does not predict future results.
Are PMV Pharmaceuticals and Zhengye Biotechnology in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.